Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.62 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.59 |
| ▸ | WNT3A | P56704 | 1/20 | 0.59 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.59 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147702 | 0.84 | KDM4E (0.73) | RAB9ANPC1PKMAGTR1TLR7 | |
| SCHEMBL6450415 | 0.82 | ALDH1A1 (0.70) | RAB9ANPC1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6451494 | 0.82 | KDM4E (0.58) | RAB9ANPC1PKMGRM4TLR7 | |
| SCHEMBL6450640 | 0.81 | KDM4E (0.60) | RAB9ANPC1PKMCTNNB1WNT3A | |
| SCHEMBL17842464 | 0.80 | CTNNB1 (0.66) | RAB9ANPC1PKMAGTR1CTNNB1 | |
| SCHEMBL28871743 | 0.79 | GAA (0.59) | RAB9ANPC1GRM4TLR7ALDH1A1 | |
| SCHEMBL4542670 | 0.78 | KDM4E (0.54) | RAB9ANPC1PKMGRM4TLR7 | |
| SCHEMBL12894824 | 0.78 | KDM4E (0.54) | RAB9ANPC1PKMAGTR1GRM4 | |
| SCHEMBL14810907 | 0.78 | KDM4E (0.67) | RAB9ANPC1PKMTLR7ALDH1A1 | |
| SCHEMBL6448607 | 0.77 | RAB9A (0.63) | RAB9ANPC1PKMALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | RAB9A 2483/4885NPC1 59/4885PKM 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.